Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

Award to support the development of molecules to inhibit BamA protein Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award a seed grant of US$610k to Justus Liebig ...

Analyst recommends Novartis as a Buy for long-term investors, BioAge a Hold, following strategic partnership for age-related ...

The increasingly fast-paced lifestyle has depleted the ordinary person’s usual diet of essential nutrients that increases the risk of atherosclerosis, despite the age group and the growth rate of ...

The month of December 2024 saw a variety of biotech deals take place to advance therapies across different stages in ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...

In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...